top of page
NCT04270409
NCT04879043
ORIC-533
NCT04270409
1/32
Multiple Myeloma Clinical Trials - Currently Recruiting
2022 - (R) NCT05347485
Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
2022 - (R) NCT05336383
Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM
2021 - (R) NCT05121103
Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL
2021 - (R) NCT05064787
Evaluating the Feasibility of a Digital Health Coaching Program Post CART
2021 - (R) NCT05000450
Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM
2021 - (R) NCT04879043
Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM
2021 - (R) NCT04855136
Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
2020 - (R) NCT04614636
FT538 in Subjects With Advanced Hematologic Malignancies
2020 - (R) NCT04582539
Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma
2020 - (R) NCT04354246
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
2019 - (R) NCT04171843
Phase 1/2: Allogeneic anti-BCMA CAR T cells PBCAR269A With or Without Nirogacestat RRMM
2019 - (R) NCT04142619
Phase 1 - UCART Targeting CS1 - allogenic T cells with anti- CS1 CAR - RRMM (MELANI-01)
2019 - (R) NCT03997968
Phase 1/2: A Phase 1/2 Study of CYT-0851, Oral RAD51 Inhibitor, in B-Cell Malignancies
2019 - (R) NCT03989414
Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
2019 - (R) NCT03915184
Phase 1 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory
2019 - (Active) NCT03984097
Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard Regimens NDMM
2018 - (R) NCT03761108
Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
2018 - (R) NCT03601078
Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
2018 - (R) NCT03530683
Phase 1: A Trial of TTI-622 in Patients With Advanced Hem. Malignancies (TTI-622-01)
2017 - (R) NCT03374085
Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
2017 - (R) NCT03287908
Phase 1/2: AMG 701 Montherapy With Pomalidomide +/- Dex in Relapsed Multiple Myeloma
2017 - (R) NCT03275103
Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM
2017 - (Completed) NCT03288493
Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Myeloma
NDMM
2020 - (R) NCT04268498
Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
2019 - (R) NCT04071457
Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC
2019 - (R) NCT03989414
Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
2019 - (R) NCT03901963
Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
MGUS/SMM
2021 - (R) NCT05136807
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
2020 - (R) NCT04512235
Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis
2020 - (R) NCT04504825
Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
2020 - (R) NCT04270409
Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)
2019 - (R) NCT03937635
Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM
2018 - (R) NCT03631043
Phase 1 - Personalized Vaccine in Treating Participants With Smoldering MM
bottom of page